Impact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis
| dc.contributor.author | Toledo Zavaleta, Diana Isabel | |
| dc.contributor.author | Cartanyà Hueso, Àurea | |
| dc.contributor.author | Pagès Fernández, Constança | |
| dc.contributor.author | Morros Pedrós, Rosa | |
| dc.contributor.author | Giner Soriano, Maria | |
| dc.contributor.author | Domínguez García, Àngela | |
| dc.contributor.author | Vilaplana Carnerero, Carles | |
| dc.contributor.author | Tor Roca, Alba | |
| dc.contributor.author | Grau, Maria | |
| dc.date.accessioned | 2026-10-22T15:39:05Z | |
| dc.date.available | 2026-10-22T15:39:05Z | |
| dc.date.issued | 2026-06-26 | |
| dc.date.updated | 2026-10-22T15:39:05Z | |
| dc.description.abstract | Background/Objectives: The study’s goal is to assess the association between long-term statin therapy and influenza incidence, influenza severity, and all-cause mortality. Methods: Two population-based dynamic cohorts (exposed and unexposed to statins) were followed from 2010 to 2019. Participants were 60 years or older; frail patients were excluded. The primary outcomes were influenza incidence, influenza-related intensive care unit (ICU) admission as a proxy for severity, and all-cause mortality. The exposed cohort comprised new statin users with a minimum of two pharmacy invoices within 90 days of enrollment. Adjusted risk ratios (aRRs) for influenza incidence, ICU admission, and mortality rate were calculated using Poisson regression. Results: The initial study population of 639,564 individuals was evenly split into exposed (319,782) and unexposed (319,782) cohorts; mean age was 71 years (standard deviation: 8 years), and 57% were women. Compared to non-users, new statin users showed a higher influenza incidence [9.39 (95% confidence interval: 9.36–9.42) vs. 7.64 (7.61–7.66) per 1000 person-years], ICU admission [1.65 (1.65–1.66) vs. 1.36 (1.35–1.36) per 1000 person-years], and overall mortality rate [97.09 (96.75–97.43) vs. 94.15 (93.82–94.47) per 1000 person-years]. Adjusted analysis revealed no significant association between statin use and influenza incidence [aRR: 1.04 (0.98–1.10)] or influenza-related ICU admission [aRR: 1.03 (0.89–1.19)] and shifted the effect on mortality from harmful to beneficial [aRR: 0.88 (0.87–0.89)]. Conclusions: Despite new users’ greater vulnerability at the start of treatment, our findings indicate that statins do not influence influenza incidence or severity but reduce all-cause mortality, warranting further exploration of their anti-inflammatory properties. | |
| dc.format.extent | 14 p. | |
| dc.format.mimetype | application/pdf | |
| dc.identifier.idgrec | 772802 | |
| dc.identifier.uri | https://hdl.handle.net/2445/232272 | |
| dc.language.iso | eng | |
| dc.publisher | MDPI | |
| dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/pharma5020010 | |
| dc.relation.ispartof | Pharmacoepidemiology, 2026, vol. 5, num.2 | |
| dc.relation.uri | https://doi.org/10.3390/pharma5020010 | |
| dc.rights | cc-by (c) Toledo, D. et al., 2026 | |
| dc.rights.accessRights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject.classification | Estatines (Medicaments cardiovasculars) | |
| dc.subject.classification | Grip | |
| dc.subject.classification | Morbiditat | |
| dc.subject.other | Statins (Cardiovascular agents) | |
| dc.subject.other | Influenza | |
| dc.subject.other | Morbidity | |
| dc.title | Impact of Long-Term Statin Therapy on Influenza Incidence and Overall Mortality: A Real-World Data Analysis | |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion |
Fitxers
Paquet original
1 - 1 de 1